Research Papers:

Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma

Pierre Boyé _, Emmanuelle David, François Serres, Quentin Pascal, Franck Floch, Kévyn Geeraert, Virginie Coste, Laurent Marescaux, Sébastien Cagnol, Jean-Yves Goujon, Maxim Egorov, Ronan Le Bot and Dominique Tierny

PDF  |  Full Text  |  How to cite

Oncotarget. 2020; 11:4281-4292. https://doi.org/10.18632/oncotarget.27801

Metrics: PDF 1049 views  |   Full Text 1997 views  |   ?  


Pierre Boyé1,2,4, Emmanuelle David3, François Serres1,2, Quentin Pascal1, Franck Floch2, Kévyn Geeraert2, Virginie Coste1, Laurent Marescaux2, Sébastien Cagnol3, Jean-Yves Goujon3, Maxim Egorov3, Ronan Le Bot3 and Dominique Tierny1,2

1 Oncovet Clinical Research (OCR), Parc Eurasanté, Loos, France

2 Oncovet, Villeneuve d’Ascq, France

3 Atlanthera, Saint Herblain, France

4 Department of Small Animal Teaching Hospital, The Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, UK

Correspondence to:

Pierre Boyé,email: [email protected]

Keywords: bisphosphonate; bone targeting; canine; doxorubicin; osteosarcoma

Received: September 21, 2020     Accepted: October 27, 2020     Published: November 17, 2020

Copyright: © 2020 Boyé et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Purpose: 12b80 combines doxorubicin bound to a bone targeting hydroxybisphosphonate vector using a pH-sensitive linker, designed to specifically trigger doxorubicin release in an acidic bone tumor microenvironment. This phase I study aimed to determine the safety and toxicity profiles of 12b80 in dogs with naturally occurring osteosarcoma, with the objective to translate findings from dogs to humans.

Experimental Design: Ten client-owned dogs with osteosarcoma were enrolled in an accelerated dose-titration design followed by 3 + 3 design. Dogs received three cycles of 12b80 intravenous injection at 4 mg/kg (n = 1), 6 mg/kg (n = 2), 8 mg/kg (n = 3), and 10 mg/kg (n = 4). Endpoints included safety, tolerability, maximum tolerated dose (MTD), and dose-limiting toxicity (DLT).

Results: The MTD of 12b80 was 8 mg/kg (i.e., equivalent dose of doxorubicin of 110 mg/m2, range: 93–126). Most adverse events included grade ≤ 2 gastrointestinal disorders and hypersensitivity reactions. No hematological or cardiac DLT were observed at any dose tested.

Conclusions: In dogs, 12b80 is overall well tolerated and expends the MTD of doxorubicin up to four times the standard dose of 30 mg/m2. These results demonstrate the potential therapeutic benefit of 12b80 in canine and human osteosarcoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27801